Oncology Corporate Profile
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of selective G protein-coupled receptor antagonists for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company recently completed a successful Phase I study in solid tumors and has begun additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies.
This company does not have any pipeline products